7-Methyl-4-phenyl-3-phenylmethoxy-[1]benzofuro[2,3-b]pyridin-6-ol | 1407992-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 7-Methyl-4-phenyl-3-phenylmethoxy-[1]benzofuro[2,3-b]pyridin-6-ol
• 英文别名: 7-methyl-4-phenyl-3-phenylmethoxy-[1]benzofuro[2,3-b]pyridin-6-ol
• CAS: 1407992-97-5
• 化学式: C₂₅H₁₉NO₃
• 分子量: 381.431
• InChiKey: CJWAJDFFNKNLST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  55.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  、 甲基苯醌 在 高氯酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 甲基氢醌 、 7-Methyl-4-phenyl-3-phenylmethoxy-[1]benzofuro[2,3-b]pyridin-6-ol
  参考文献：
  名称：

  Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases

  摘要：

  Alzheimer disease (AD) turned out to be a multifactorial process leading to neuronal decay. So far merely single target structures which attribute to the AD progression have been considered to develop specific drugs. However, such drug developments have been disappointing in clinical stages. Multitargeting of more than one target structure determines recent studies of developing novel lead compounds. Protein kinases have been identified to contribute to the neuronal decay with CDK1, GSK-3 beta and CDK5/p25 being involved in a pathological tau protein hyperphosphorylation. We discovered novel lead structures of the dihydroxy-1-aza-9-oxafluorene type with nanomolar activities against CDK1, GSK-3 beta and CDK5/p25. Structure-activity relationships (SAR) of the protein kinase inhibition are discussed within our first compound series. One nanomolar active compound profiled as selective protein kinase inhibitor. Bioanalysis of a harmless cellular toxicity and of the inhibition of tau protein phosphorylation qualifies the compound for further studies. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.09.006

文献信息

• Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases
  作者：Volkmar Tell、Max Holzer、Lydia Herrmann、Kazem Ahmed Mahmoud、Christoph Schächtele、Frank Totzke、Andreas Hilgeroth

  DOI：10.1016/j.bmcl.2012.09.006

  日期：2012.11

  Alzheimer disease (AD) turned out to be a multifactorial process leading to neuronal decay. So far merely single target structures which attribute to the AD progression have been considered to develop specific drugs. However, such drug developments have been disappointing in clinical stages. Multitargeting of more than one target structure determines recent studies of developing novel lead compounds. Protein kinases have been identified to contribute to the neuronal decay with CDK1, GSK-3 beta and CDK5/p25 being involved in a pathological tau protein hyperphosphorylation. We discovered novel lead structures of the dihydroxy-1-aza-9-oxafluorene type with nanomolar activities against CDK1, GSK-3 beta and CDK5/p25. Structure-activity relationships (SAR) of the protein kinase inhibition are discussed within our first compound series. One nanomolar active compound profiled as selective protein kinase inhibitor. Bioanalysis of a harmless cellular toxicity and of the inhibition of tau protein phosphorylation qualifies the compound for further studies. (C) 2012 Published by Elsevier Ltd.